Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 313

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

MitraClip® Therapy in Patients with End-Stage Systolic Heart Failure

Franzen, Olaf, van der Heyden, Jan, Baldus, Stephan, Schlüter, Michael, Schillinger, Wolfgang, Butter, Christian, Hoffmann, Rainer, Corti, Roberto, Pedrazzini, Giovanni, Swaans, Martin J., Neuss, Michael, Rudolph, Volker, Sürder, Daniel, Grünenfelder, Jürg, Eulenburg, Christine, Reichenspurner, Hermann, Meinertz, Thomas, Auricchio, Angelo · 2011 · European Journal of Heart Failure

Abstract

Aims: To assess the feasibility, short-term durability and clinical outcomes of MitraClip® therapy for mitral regurgitation (MR) in patients with end-stage heart failure and a severely reduced left ventricular (LV) ejection fraction. Methods and results: We analysed retrospectively collected data from seven European centres. Included in the study were 50 heart failure patients [mean age 70 ± 11 years, 38 men (76%)] with a LV ejection fraction ≤25% and MR of at least grade 3+. All patients had functional MR, were in New York Heart Association (NYHA) functional class III or IV, and their mean logistic EuroSCORE was 34%. The patients underwent a total of 53 MitraClip® procedures; one or more clips were implanted in 50 procedures (48 patients), for an acute procedural success rate of 94%. Severity of MR was reduced in all successfully treated patients, 44 (92%) were discharged with MR ≤2+. Thirty-day mortality was 6%; cumulative survival at 6 months was 81.2%. Clinical and echocardiographic 6-month follow-up data were obtained from 32 and 31 successfully treated patients, respectively. At 6 months, MR ≤2+ was present in 27 (87%) of 31 patients, and 23 (72%) of 32 patients were in NYHA functional class I or II. Six-minute walk distance improved significantly, and significant reductions in LV volumes indicative of reverse LV remodelling were concordant with significant reductions in N-terminal pro-brain natriuretic peptide plasma levels. Conclusion: MitraClip® therapy reduces functional MR in patients with end-stage heart failure and marked LV dysfunction and entails clinical benefit at 6 months.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurjhf/hfr029

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 313

Metadata

Authors
Franzen, O., van der Heyden, J., Baldus, S., Schlüter, M., Schillinger, W., Butter, C., Hoffmann, R., Corti, R., Pedrazzini, G., Swaans, M. J., Neuss, M., Rudolph, V., Sürder, D., Grünenfelder, J., Eulenburg, C., Reichenspurner, H., Meinertz, T., & Auricchio, A.
Venue
European Journal of Heart Failure
Published
2011-05-01
Volume
13
Issue
5
Pages
569-576
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2019509109
Cited by
313
References
15
FWCI
30.97
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MitraClip® Therapy in Patients with End-Stage Systolic Heart Failure. https://app.cochat.ai/papers/10.1093/eurjhf/hfr029
The paper
Franzen, O., van der Heyden, J., Baldus, S., Schlüter, M., Schillinger, W., Butter, C., Hoffmann, R., Corti, R., Pedrazzini, G., Swaans, M. J., Neuss, M., Rudolph, V., Sürder, D., Grünenfelder, J., Eulenburg, C., Reichenspurner, H., Meinertz, T., & Auricchio, A. (2011). MitraClip® Therapy in Patients with End-Stage Systolic Heart Failure. European Journal of Heart Failure. https://doi.org/10.1093/eurjhf/hfr029

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.